Primary cutaneous DLBCL non-GCB type: challenges of a rare case

Sica, Antonello; Vitiello, Paola; Caccavale, Stefano; Sagnelli, Caterina; Calogero, Armando; Doraro, Concetta Anna; Pastore, Fiorella; Ciardiello, Fortunato; Argenziano, Giuseppe; Reginelli, Alfonso; Cappabianca, Salvatore; Franco, Renato; Ronchi, Andrea

doi:10.1515/med-2020-0018

Cited by 29 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This strategy consists of observing and treating the patient only when the disease shows systemic symptoms, bulky mass (<7 cm), symptomatic splenomegaly, progressive leukemization, and serum effusions. Follow-up is usually planned every 6 months with a complete skin and lymph node examination (17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis. They include ∼25% of all cutaneous lymphomas and are classified in three major subgroups (World Health Organization (WHO) 2017): primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center cell lymphoma (PCFCL), and diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). This classification also includes some less common entities such as intravascular large B-cell lymphoma. Recently, WHO-EORTC added Epstein-Barr virus positive (EBV+) mucocutaneous ulcer, as a new provisional distinct entity, to cutaneous B-cell lymphomas. PCBCLs are classically characterized by patches, plaques, or nodules showing great variability for color, shape, and location. Diagnosis requires histological examination with immunohistochemical staining. In general, therapeutic options depend on the exact histological and immunohistochemical classification, disease presentation, and risk assessment. PCMZL and PCFCL are considered indolent lymphomas with a good prognosis and are associated with 5-year disease-specific survival ≥ 95%. In contrast, PCDLBCL, LT is considered an aggressive lymphoma with a survival rate in 5 years of lower than 60%. Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments as compared to patients with generalized lesions or refractory disease or extracutaneous involvement. Therapeutic choice includes observation, local, or systemic therapy based on histology and disease extension. Patient management is multidisciplinary, including dermatologists, pathologists, hemato-oncologists, and radiation oncologists.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Associated to treatment, adequate nutrition, muscle rehabilitation and psychological support allow a better chance of recovery, our patient in on reliable example of this [23,24].…”

Section: Discussionmentioning

confidence: 95%

“…The diagnosis and management of CLL impact quality of life (QoL) [37], and also the sedentary lifestyle of the majority of cancer patients play a negative effect on QoL [5,6,[37][38][39][40][41][42] and on their survival [11]. However, randomized studies have shown the substantial improvement in QoL of cancer patients due to an adequate program of physical activity [23][24][25]34] and impact the cancer survival [7], since it reduces the peak oxygen consumption, improves physical capacity, increases self-esteem, reduces accumulated stress, and promotes relaxation [8,11]. Consequently, physical activity is strongly recommended for healthy individuals to improve cardiorespiratory and muscular fitness, bone health, and in general to reduce the risk of non-communicable diseases, depression, and cognitive decline [11] The correct application of an exercise program may have a beneficial effect in onco-hematologic patients, since it may improve the function of the immune system (regulation of macrophages and natural killer cells interacting with cancer cells) [9,10] and provide a protective effect against cancer progression.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An Anecdotal Case Report of Chronic Lymphatic Leukemia with del(11q) Treated with Ibrutinib: Artificial Nourishment and Physical Activity Program

Sica

Sagnelli

Papa

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Chronic lymphatic leukemia (CLL) is the most frequent type of leukemia in western countries and when association with del(11q) is correlated with a worse prognosis. We reported the clinical case of an 80-year-old patient with CLL related to del(11q) and a BMI of 16.4 kg/m2, who presented a voluminous mass in abdominal cavity (23 × 14 × 4 cm) which occupied the whole of the mesentery and the retroperitoneal space, treated with ibrutinib, adequate nutrition, and a program of physical activity. He showed a great improvement under ibrutinib therapy and took to artificial nourishment and adequate muscle rehabilitation until he recovered his autonomy. In August 2018, a 5-days-a-week training program was started: Physical activity for at least 20 min consisting of a fast walk in the open air three times a week and a moderate physical activity in the remaining two days of at least 20 consecutive minutes (cycling at a regular pace, carrying light weights). The exercise program included also aerobic, upper and lower limb resistance training, chore stability and stretches. The physical condition further improved and remained excellent throughout the follow-up period. In December 2018, his clinical condition was quite normal; a CT showed a great decrease of all lymphoadenomegaly, and FISH test did not show del(11q). He continued to cultivate his land, while still being treated with ibrutinib. The combination of the right therapy, adequate nutrition, and muscle rehabilitation is the best solution to improve the clinical condition of old cachectic CLL del(11q) patient.

show abstract

“…Over time, a stimulation change may occur due to cellular changes in tissues surrounding the electrodes caused by the displacement of the electrodes, loosening of the electrical connections, defects in the lead, or alterations in the charge of the batteries. Spinal cord stimulation is mainly applied in the failed back surgery syndrome (FBSS), neuropathic pain, peripheral ischemic pain, amputation pain and visceral pain (28,29), and disorders involving chronic pain lasting for years.…”

mentioning

confidence: 99%